A Phase 3 Clinical Study for People With Relapsed or Refractory AL Amyloidosis

Deciding whether to join a clinical study is a big decision. You will want to gather as much information as possible before you make your decision. Below are answers to some key questions designed to give you a better understanding of the study and its goals. You can also visit ClinicalTrials.gov for more information.

Rate of hospitalization for heart failure or progression to end-stage renal disease or death at 2 years

In addition to the primary endpoints, there are additional endpoints. These are results that are measured at the end of a study, but do not determine the overall success of the study. Some additional endpoints include:

Overall survival (OS)

Progression-free survival (PFS)

Number of patients with cardiac and/or kidney response

Safety

How many patients will participate in this study?

Approximately 250 patients will participate in this study worldwide.

How long will the study last?

The study is estimated to be completed in August 2018.

What should I know about MLN9708?

MLN9708 is an investigational targeted anti-cancer drug given orally. MLN9708 is being studied in multiple myeloma, various hematologic malignancies, and solid tumors.